Faron Pharmaceuticals Oy banner

Intrinsic Value

The intrinsic value of Faron Pharmaceuticals Oy (4FR) under the Base Case is 0.24 EUR per share. Compared with the current market price of 0.33 EUR, the stock appears Overvalued by 27% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

4FR Intrinsic Value
€0.24
Overvaluation 27%
Intrinsic Value
Price €0.33
Alert me when 4FR is below its intrinsic value
Today €0.19 · 41.9% below the current price

We don’t have enough historical valuation data to make this comparison.

Alternatives to 4FR

Fundamental Analysis

What Faron Pharmaceuticals Oy Does

Biotechnology Health Care

Faron Pharmaceuticals is a drug development company focused on medicines that change how the immune system behaves in cancer and severe inflammation. Its main work is to discover and test new drug candidates, especially bexmarilimab, an immunotherapy aimed at helping the body’s own defenses attack tumors. The company is not a mass-market drug seller; it is a research-stage biotech trying to turn lab findings into approved medicines.

Headquarters
Finland FI
Employees
33
IPO date
Nov 17, 2015
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue 4FR Research

Decided on Faron Pharmaceuticals Oy? Get an email when 4FR reaches the price you’d buy at. Free with an account.

Other Faron Pharmaceuticals Oy listings

What is the Intrinsic Value of one 4FR stock?

The intrinsic value for Faron Pharmaceuticals Oy (4FR) under the Base Case is 0.24 EUR.

Is 4FR stock undervalued or overvalued?

Compared with the current market price of 0.33 EUR, the stock appears Overvalued by 27% .

How reliable are our estimates? See how past valuations played out
Back to Top